跳到正文
NAFDAC 药品质量警报与召回·精选AI 评分64

NAFDAC 发布第 042/2026 号公共警报,通报在卡诺州查获疑似劣质和伪造的 BPPL 蒿甲醚/苯芴醇 80mg/480mg

Public Alert No. 042/2026-Alert on the Seizure of Suspected Substandard and Falsified BPPL Artemether/Lumefantrine 80mg/480mg

AI 导读

NAFDAC 发布第 042/2026 号公共警报,通报在卡诺州协调批发中心(CWC)的上市后监督活动中查获一批疑似劣质和伪造的蒿甲醚/苯芴醇 80mg/480mg。

推荐理由

警报列出被查获产品的批号、伪造注册号及标签未标注上市许可持有人等识别信息,可供核对流通渠道时比对。

正文 · 原文

The National Agency for Food and Drug Administration and Control (NAFDAC) is notifying healthcare providers, importers, distributors, retailers, Patent and Proprietary Medicine Vendors (PPMVs), and the general public of the seizure of a suspected Substandard and Falsified (SF) antimalarial medicine, Artemether/Lumefantrine 80mg/480mg, purportedly manufactured by Bandaram Pharma Packleh Ltd (BPPL), India.

The product was intercepted by NAFDAC officials during routine Post-Market Surveillance activities at the Coordinated Wholesale Centre (CWC), Kano State. Verification conducted by NAFDAC confirmed that the NAFDAC Registration Number 02-3457 displayed on the product is fake and does not exist in the Agency’s registration database.

The product label does not indicate the MAH information.

Given that Artemether/Lumefantrine is used in the treatment of malaria, the circulation and use of falsified products may result in treatment failure, worsening of disease, development of drug resistance, and other serious public health consequences. The product has therefore been classified as a Falsified (F) Medical Product.

Product Details

Product Information

Details

Product Name

Artemether/Lumefantrine 80mg/480mg

Purported Manufacturer

Bandaram Pharma Packleh Ltd (BPPL)

Manufacturer’s Address

Plot No. 1 & 2, Number 13, Mirgila, Nagar, India

NAFDAC Registration Number

02-3457 (Fake)

Batch Number

BP5203

Manufacturing Date

10/2024

Expiry Date

09/2027

Marketing Authorisation Holder (MAH)

Not declared on the product label

  

Product Photo

Fig: Front, Back and Side view of the secondary package

NAFDAC remains committed to safeguarding public health through continuous surveillance and regulatory actions aimed at preventing the circulation of substandard and falsified medical products in Nigeria.

Advice to Healthcare Professionals and the Public

Healthcare professionals and members of the public are advised to:

  • Exercise caution and avoid the purchase, sale, supply, or use of the affected product.
  • Obtain medicines only from authorised and licensed suppliers.
  • Carefully check the authenticity of medicines before purchase and use.
  • Report any suspected sale, distribution, or use of the product to the nearest NAFDAC office.

Reporting of Adverse Events

Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, call NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng

Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med- safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng

For complaints, you can call the Reforms Unit on the following lines: 09097630506, 09097630507, or email: reforms@nafdac.gov.ng

Furthermore, note that this notice will be uploaded to the WHO Global Surveillance and Monitoring System (GSMS).

NAFDAC………. Customer-focused, Agency-minded!!!

Was this helpful?

Yes

No

Thanks for your feedback!

来源:NAFDAC 药品质量警报与召回 · nafdac.gov.ng